Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Achieve Life Sciences, Inc. stock logo
ACHV
Achieve Life Sciences
$6.71
-1.1%
$7.07
$2.62
▼
$8.64
$689.96M2.421.36 million shs1.09 million shs
Bausch Health Cos Inc. stock logo
BHC
Bausch Health Cos
$8.22
-4.0%
$6.75
$4.33
▼
$9.04
$3.08B0.32.72 million shs3.74 million shs
HUTCHMED (China) Limited Sponsored ADR stock logo
HCM
HUTCHMED
$13.26
-1.4%
$14.10
$9.77
▼
$16.33
$2.31B0.350,011 shs32,798 shs
MBX Biosciences, Inc. stock logo
MBX
MBX Biosciences
$49.55
-7.2%
$55.07
$26.00
▼
$72.64
$2.46B0.17637,827 shs581,881 shs
7 Energy Stocks to Buy and Hold Forever Cover

Oil still powers the global economy, but AI is reshaping the energy opportunity. Discover seven stocks spanning traditional energy, infrastructure, and next-generation power.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Achieve Life Sciences, Inc. stock logo
ACHV
Achieve Life Sciences
0.00%0.00%+3.00%-16.08%+55.21%
Bausch Health Cos Inc. stock logo
BHC
Bausch Health Cos
-1.79%+3.88%+33.88%+33.57%+41.83%
HUTCHMED (China) Limited Sponsored ADR stock logo
HCM
HUTCHMED
-3.86%-9.43%-8.75%+6.49%-7.43%
MBX Biosciences, Inc. stock logo
MBX
MBX Biosciences
-0.02%-2.02%-0.17%-19.48%+95.00%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Achieve Life Sciences, Inc. stock logo
ACHV
Achieve Life Sciences
$6.71
-1.1%
$7.07
$2.62
▼
$8.64
$689.96M2.421.36 million shs1.09 million shs
Bausch Health Cos Inc. stock logo
BHC
Bausch Health Cos
$8.22
-4.0%
$6.75
$4.33
▼
$9.04
$3.08B0.32.72 million shs3.74 million shs
HUTCHMED (China) Limited Sponsored ADR stock logo
HCM
HUTCHMED
$13.26
-1.4%
$14.10
$9.77
▼
$16.33
$2.31B0.350,011 shs32,798 shs
MBX Biosciences, Inc. stock logo
MBX
MBX Biosciences
$49.55
-7.2%
$55.07
$26.00
▼
$72.64
$2.46B0.17637,827 shs581,881 shs
7 Energy Stocks to Buy and Hold Forever Cover

Oil still powers the global economy, but AI is reshaping the energy opportunity. Discover seven stocks spanning traditional energy, infrastructure, and next-generation power.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Achieve Life Sciences, Inc. stock logo
ACHV
Achieve Life Sciences
0.00%0.00%+3.00%-16.08%+55.21%
Bausch Health Cos Inc. stock logo
BHC
Bausch Health Cos
-1.79%+3.88%+33.88%+33.57%+41.83%
HUTCHMED (China) Limited Sponsored ADR stock logo
HCM
HUTCHMED
-3.86%-9.43%-8.75%+6.49%-7.43%
MBX Biosciences, Inc. stock logo
MBX
MBX Biosciences
-0.02%-2.02%-0.17%-19.48%+95.00%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Achieve Life Sciences, Inc. stock logo
ACHV
Achieve Life Sciences
3.00
Buy$15.50131.17% Upside
Bausch Health Cos Inc. stock logo
BHC
Bausch Health Cos
1.86
Reduce$8.756.45% Upside
HUTCHMED (China) Limited Sponsored ADR stock logo
HCM
HUTCHMED
2.67
Moderate Buy$14.8712.11% Upside
MBX Biosciences, Inc. stock logo
MBX
MBX Biosciences
2.79
Moderate Buy$87.3076.19% Upside

Current Analyst Ratings Breakdown

Latest ACHV, MBX, HCM, and BHC Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
11/12/2026
MBX Biosciences, Inc. stock logo
MBX
MBX Biosciences
Initiated CoverageBuy$90.00
11/11/2026
Bausch Health Cos Inc. stock logo
BHC
Bausch Health Cos
Boost Price TargetEqual Weight$7.00 ➝ $9.00
11/5/2026
Bausch Health Cos Inc. stock logo
BHC
Bausch Health Cos
DowngradeStrong-Buy ➝ Hold
10/29/2026
Bausch Health Cos Inc. stock logo
BHC
Bausch Health Cos
Reiterated RatingSell (D)
10/29/2026
Bausch Health Cos Inc. stock logo
BHC
Bausch Health Cos
Boost Price TargetHold$6.50 ➝ $8.00
10/29/2026
Bausch Health Cos Inc. stock logo
BHC
Bausch Health Cos
Boost Price TargetSector Perform$9.00 ➝ $10.00
10/27/2026
MBX Biosciences, Inc. stock logo
MBX
MBX Biosciences
Reiterated RatingMarket Outperform
10/23/2026
Achieve Life Sciences, Inc. stock logo
ACHV
Achieve Life Sciences
Reiterated RatingBuy
10/20/2026
HUTCHMED (China) Limited Sponsored ADR stock logo
HCM
HUTCHMED
UpgradeSell (D) ➝ Sell (D+)
10/15/2026
MBX Biosciences, Inc. stock logo
MBX
MBX Biosciences
Reiterated RatingSell (D-)
10/12/2026
MBX Biosciences, Inc. stock logo
MBX
MBX Biosciences
Boost Price TargetBuy$70.00 ➝ $84.00
(Data available from 11/20/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Achieve Life Sciences, Inc. stock logo
ACHV
Achieve Life Sciences
N/AN/AN/AN/A$0.40 per shareN/A
Bausch Health Cos Inc. stock logo
BHC
Bausch Health Cos
$10.27B0.30$6.85 per share1.20($0.91) per share-9.03
HUTCHMED (China) Limited Sponsored ADR stock logo
HCM
HUTCHMED
$549.12M4.21$2.56 per share5.19$7.17 per share1.85
MBX Biosciences, Inc. stock logo
MBX
MBX Biosciences
N/AN/AN/AN/A$9.52 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Achieve Life Sciences, Inc. stock logo
ACHV
Achieve Life Sciences
-$54.65M-$1.55N/AN/AN/AN/A-511.12%-82.35%N/A
Bausch Health Cos Inc. stock logo
BHC
Bausch Health Cos
$157M-$2.29N/A2.07N/A-7.57%-401.73%7.34%N/A
HUTCHMED (China) Limited Sponsored ADR stock logo
HCM
HUTCHMED
$456.91MN/AN/A60.28N/AN/AN/AN/AN/A
MBX Biosciences, Inc. stock logo
MBX
MBX Biosciences
-$86.97M-$3.07N/AN/AN/AN/A-34.37%-32.72%N/A

Latest ACHV, MBX, HCM, and BHC Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/10/2026Q3 2026
Achieve Life Sciences, Inc. stock logo
ACHV
Achieve Life Sciences
-$0.1997-$0.11+$0.0897-$0.11$10.65 millionN/A
11/9/2026Q3 2026
MBX Biosciences, Inc. stock logo
MBX
MBX Biosciences
-$0.80-$1.29-$0.49-$1.29N/AN/A
10/28/2026Q3 2026
Bausch Health Cos Inc. stock logo
BHC
Bausch Health Cos
$1.25$1.77+$0.52N/A$2.72 billion$2.90 billion
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Achieve Life Sciences, Inc. stock logo
ACHV
Achieve Life Sciences
N/AN/AN/AN/AN/A
Bausch Health Cos Inc. stock logo
BHC
Bausch Health Cos
N/AN/AN/AN/AN/A
HUTCHMED (China) Limited Sponsored ADR stock logo
HCM
HUTCHMED
N/AN/AN/AN/AN/A
MBX Biosciences, Inc. stock logo
MBX
MBX Biosciences
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Achieve Life Sciences, Inc. stock logo
ACHV
Achieve Life Sciences
0.87
0.95
0.95
Bausch Health Cos Inc. stock logo
BHC
Bausch Health Cos
N/A
1.56
1.22
HUTCHMED (China) Limited Sponsored ADR stock logo
HCM
HUTCHMED
0.06
5.64
5.50
MBX Biosciences, Inc. stock logo
MBX
MBX Biosciences
N/A
19.58
19.58

Institutional Ownership

CompanyInstitutional Ownership
Achieve Life Sciences, Inc. stock logo
ACHV
Achieve Life Sciences
33.52%
Bausch Health Cos Inc. stock logo
BHC
Bausch Health Cos
78.65%
HUTCHMED (China) Limited Sponsored ADR stock logo
HCM
HUTCHMED
8.82%
MBX Biosciences, Inc. stock logo
MBX
MBX Biosciences
N/A

Insider Ownership

CompanyInsider Ownership
Achieve Life Sciences, Inc. stock logo
ACHV
Achieve Life Sciences
1.80%
Bausch Health Cos Inc. stock logo
BHC
Bausch Health Cos
20.67%
HUTCHMED (China) Limited Sponsored ADR stock logo
HCM
HUTCHMED
3.60%
MBX Biosciences, Inc. stock logo
MBX
MBX Biosciences
31.09%
CompanyEmployeesShares OutstandingFree FloatOptionable
Achieve Life Sciences, Inc. stock logo
ACHV
Achieve Life Sciences
28102.90 million101.05 millionOptionable
Bausch Health Cos Inc. stock logo
BHC
Bausch Health Cos
20,300374.40 million297.01 millionOptionable
HUTCHMED (China) Limited Sponsored ADR stock logo
HCM
HUTCHMED
1,796174.47 million168.19 millionOptionable
MBX Biosciences, Inc. stock logo
MBX
MBX Biosciences
6349.66 million34.22 millionOptionable

Recent News About These Companies

MBX Biosciences (MBX) Stock Looks Above Fair Value On Phase 3 Progress
MBX Biosciences (NASDAQ:MBX) Shares Gap Down - Time to Sell?
Brokers Issue Forecasts for MBX Biosciences FY2026 Earnings
HC Wainwright Forecasts MBX Biosciences FY2026 Earnings
MBX Biosciences, Inc. (MBX) Receives a Buy from Oppenheimer
MBX Biosciences, Inc. (MBX) Receives a Buy from Oppenheimer
MBX Biosciences (NASDAQ:MBX) CEO Sells 4,893 Shares of Stock
MBX Biosciences (NASDAQ:MBX) Now Covered by HC Wainwright

New MarketBeat Followers Over Time

Media Sentiment Over Time

Achieve Life Sciences stock logo

Achieve Life Sciences NASDAQ:ACHV

$6.70 -0.08 (-1.11%)
Closing price 11/9/2026
Extended Trading
$6.70 0.00 (0.00%)
As of 11/9/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Achieve Life Sciences, Inc., a clinical-stage pharmaceutical company, develops and commercializes cytisinicline for smoking cessation and nicotine addiction. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms. It has license and supply agreement with Sopharma AD and University of Bristol Achieve Life Sciences, Inc. is based in Vancouver, Canada.

Bausch Health Cos stock logo

Bausch Health Cos NYSE:BHC

$8.22 -0.34 (-3.97%)
Closing price 03:59 PM Eastern
Extended Trading
$8.21 -0.01 (-0.11%)
As of 04:22 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Bausch Health Companies Inc. operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health. The company operates through five segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb. The Salix segment provides gastroenterology products in the United States. The International segment sells aesthetic medical devices, branded pharmaceuticals, generic pharmaceuticals, and OTC products internationally. The Solta Medical segment engages in the sale of aesthetic medical devices. The Diversified segment offers pharmaceutical products in the areas of neurology and certain other therapeutic classes; generic products; ortho dermatologic; and dentistry products in the United States. The Bausch + Lomb segment offers products in the areas of vision care, surgical, and ophthalmic pharmaceuticals products. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. is headquartered in Laval, Canada.

HUTCHMED stock logo

HUTCHMED NASDAQ:HCM

$13.26 -0.19 (-1.41%)
Closing price 03:59 PM Eastern
Extended Trading
$13.24 -0.02 (-0.12%)
As of 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

HUTCHMED (China) Ltd. is a holding company, which engages in the research and development, manufacture, and sale of pharmaceuticals and health-oriented consumer products. It operates through the Oncology/Immunology and Other Ventures segments. The Oncology/Immunology segment includes the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The Other Ventures segment involves the other commercial businesses which include the sales, marketing, manufacture, and distribution of prescription drugs and healthcare products. The company was founded on December 18, 2000 and is headquartered in Hong Kong.

MBX Biosciences stock logo

MBX Biosciences NASDAQ:MBX

$49.55 -3.86 (-7.23%)
Closing price 04:00 PM Eastern
Extended Trading
$49.58 +0.03 (+0.05%)
As of 04:15 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

We are a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders. Our company was founded by global leaders with a transformative approach to peptide drug design and development. Leveraging this expertise, we designed our proprietary Precision Endocrine Peptide™, or PEPTM, platform to overcome the key limitations of unmodified and modified peptide therapies and to improve clinical outcomes and simplify disease management for patients. Our PEPs are selectively engineered to have optimized pharmaceutical properties, including extended time-action profiles and consistent drug concentrations with low peak-to-trough concentration ratios, consistent exposure to target tissues, and less frequent dosing. We are advancing a pipeline of novel candidates for endocrine and metabolic disorders with clinically validated targets, established endpoints for regulatory approval, significant unmet medical needs and large potential market opportunities. Our product candidates and programs include: • MBX 2109: Our lead product candidate, MBX 2109, is a parathyroid hormone peptide prodrug that is designed as a potential long-acting hormone replacement therapy for the treatment of chronic hypoparathyroidism, or HP. Leveraging our proprietary PEP platform, we designed MBX 2109 to treat the underlying pathophysiology of HP by providing a continuous, infusion-like exposure to parathyroid hormone, or PTH, with convenient once-weekly administration. In a Phase 1 clinical trial, MBX 2109 demonstrated a low ratio between the highest concentration of active drug observed after a dose and the concentration of active drug observed immediately prior to the next dose, or peak-to-trough ratio, which is consistent with a continuous, infusion-like profile, and an extended half-life, potentially enabling the first once-weekly PTH dosing regimen for patients with HP. MBX 2109 was generally well-tolerated with no drug-related severe or serious adverse effects. We are currently evaluating MBX 2109 in a Phase 2 clinical trial in patients with HP and dosed our first patient in this trial in August 2024. We anticipate reporting topline data in the third quarter of 2025. • MBX 1416: We are advancing MBX 1416, which is designed to be a long-acting glucagon-like peptide-1, or GLP-1, receptor antagonist, as a potential therapy for post-bariatric hypoglycemia, or PBH, a chronic complication of bariatric surgery. MBX 1416 is designed as a convenient once-weekly therapy to reduce insulin secretion and increase blood glucose to reduce the frequency and severity of hypoglycemic events. In our ongoing Phase 1 clinical trial, preliminary data regarding the way the compound is absorbed, distributed, metabolized and excreted, or pharmacokinetics, from the single ascending dose portion demonstrated that weekly subcutaneous injections resulted in dose-proportional increases in MBX 1416 exposure and a half-life supporting a once-weekly dosing regimen. We anticipate additional single ascending dose and multiple ascending dose data from our ongoing Phase 1 clinical trial in the fourth quarter of 2024. • Obesity portfolio: Our lead obesity product candidate, MBX 4291, is designed to be a long-acting and highly potent GLP-1 and glucose-dependent insulinotropic polypeptide, or GIP, receptor co-agonist prodrug with the goal of reducing dosing frequency and improving efficacy and tolerability relative to existing standards of care. In our preclinical studies, the active component of MBX 4291 demonstrated a similar activity profile and body weight loss in mice as tirzepatide, an approved weekly GLP-1/GIP co-agonist, and an extended duration of action of the active component of MBX 4291, supporting the potential for once-monthly administration. During our preclinical studies, the concentration of the active component of MBX 4291 was significantly lower than the concentration of tirzepatide during the comparison period. Although we believe MBX 4291 has the potential to be dosed less frequently, less frequent dosing would necessarily require a higher dose of MBX 4291. The results observed from our preclinical studies may not necessarily be predictive of the results of later-stage clinical trials that we may conduct. In addition, the study supporting potential duration of MBX 4291 was conducted separately from studies evaluating its effects. MBX 4291 is currently in IND-enabling studies with an anticipated investigational new drug, or IND, submission in the second quarter of 2025. Beyond MBX 4291, we have a robust discovery pipeline including multiple programs in the lead optimization stage of development. Endocrine organs secrete peptide hormones into the blood stream that act on distant organs to calibrate their function and maintain homeostasis, which impact metabolism, growth, reproduction and other bodily functions. Underproduction of a hormone, known as a hormonal deficiency, can lead to endocrine diseases, such as diabetes and HP. In addition to using peptides as hormone replacement therapies, peptide-based drugs have been developed as pharmacologic agents to treat endocrine and other diseases. However, whether as replacement therapies or novel pharmacological actions, these therapeutic peptides often have significant drawbacks. Unmodified peptides often have short half-lives, and are rapidly degraded by enzymes and swiftly cleared within minutes to hours by the liver and kidney. This often necessitates frequent, daily injections of these peptides, which can result in wide fluctuations of the peptide concentration in the bloodstream leading to diminished effectiveness of the therapy or side effects caused by high levels of the peptide. Modified peptide therapies have been developed to allow less frequent once-daily and once-weekly dosing regimens. Although these convenient, patient-friendly therapies could increase compliance and result in improved effectiveness in the real-world setting, they can still produce significant fluctuations in peptide blood levels or high peak-to-trough ratios, which can lead to side effects and limit potential efficacy. Therefore, there remains a significant unmet need to develop modified peptide therapies with extended time-action profiles and low peak-to-trough ratios that allow for less frequent injections and have the potential to provide improved efficacy, tolerability and convenience. Leveraging the proprietary technologies in our PEP platform, we are designing and developing novel peptide therapeutics with the goal of achieving four key, distinct attributes: 1) high potency, 2) high target selectivity, 3) half-lives that allow for dosing at weekly or less frequent intervals, and 4) low or flat peak-to-trough ratios to improve tolerability, thereby facilitating higher dosing and greater potential efficacy. We were founded as MBX Biosciences LLC, an Indiana limited liability company, in August 2018. We converted to a Delaware corporation in April 2019 and incorporated under the name MBX Biosciences, Inc. Our principal executive offices are located at 11711 N. Meridian Street, Suite 300, Carmel, Indiana.